Shin Nippon Biomedical Laboratories has announced results from a Phase 1 study of its intranasal zolmitriptan formulation (TRZ) for the treatment of migraine headaches. The company is developing several intranasal drugs based on its μco muco-adhesive powder carrier system and intranasal powder delivery device. According to SNBL, the study, which compared three … [Read more...] about Positive Phase 1 results for dry powder intranasal zolmitriptan
News
Merck issues statement on Nasonex patent trial
Merck has issued a statement saying that the company "firmly believes its patent for Nasonex nasal spray is valid and infringed and will vigorously defend its intellectual property rights in a bench trial against Apotex Inc. and Apotex Corp. that began in US federal court today." Merck is suing Apotex for infringing U.S. Patent No. 6,127,353, issued to Schering in … [Read more...] about Merck issues statement on Nasonex patent trial
Copley introducing new breath simulator
Copley Scientific will be introducing its new BRS 3000 breath simulator for the testing of metered dose inhalers (MDIs) and dry powder inhalers (DPIs) at RDD 2012. The company previously introduced its BRS 2000 breath simulator for nebulisers at ISAM 2011. According to the company, "The BRS 3000 allows users to precisely define and apply breathing profiles that mimic … [Read more...] about Copley introducing new breath simulator
Two inhalers finalists in the Medical Design Excellence Awards
Two dry powder inhalers have been named as finalists in the 2012 Medical Design Excellence Awards sponsored by Medical Device and Diagnostic Industry. Sun Pharmaceutical's Combitide Starhaler and Novartis's TOBI Podhaler with Pulmosphere technology are both nominated in the "General Hospital Devices and Therapetic Products" category. Cambridge Consultants received … [Read more...] about Two inhalers finalists in the Medical Design Excellence Awards
Pearl Therapeutics creates nanogram-dose MDIs
According to Pearl Therapeutics, the company has produced metered dose inhalers (MDI) with the ability to deliver a 300ng dose of glycopyrrolate (GP) per actuation. Pearl formulated the GP for the nanogram-dose inhalers using the company's porous particle cosuspension technology and has initiated a Phase 2b study to evaluate safety and efficacy of twice a day dosing … [Read more...] about Pearl Therapeutics creates nanogram-dose MDIs
British Pharmacopoeial Commission requests comment on changes to inhaled product monographs
The British Pharmacopoeial Commission is requesting comment from OINDP manufacturers regarding proposed changes to its inhaled product monographs. The BP has posted a draft document authored by its Inhaled Products Working Party and has asked that manufacturers of MDIs, DPIs, and nebulizer solutions submit comments along with any relevant data. The draft document … [Read more...] about British Pharmacopoeial Commission requests comment on changes to inhaled product monographs
OINDP specialist Mark Shepherd to attempt world record
Mark Shepherd, Respiratory Physics Lab and Workshop Manager at Team Consulting, will attempt to set a world record by climbing to the top of the Empire State Building in New York City while carrying 125 kg on his back. The attempt will take place on May 26, 2012 and will benefit the Myositis Support Group, a UK charity. To date, Shepherd has raised £370,000 through … [Read more...] about OINDP specialist Mark Shepherd to attempt world record
Jesse Zhu wins Distinguished University Professorship
The University of Western Ontario has named particle technology researcher Jesse Zhu a 2012 Distinguished University Professorship winner. Zhu, a professor and Canada Research Chair in Powder Technology Applications in the Department of Chemical and Biochemical Engineering at Western, has published a number of papers related to dry powder inhalation. Zhu has been … [Read more...] about Jesse Zhu wins Distinguished University Professorship
QVA 149 Phase 3 studies meet primary endpoints
Three Phase 3 studies of Novartis's QVA149 indacaterol /glycopyrronium bromide dry powder inhaler for the treatment of COPD have met their primary endpoints according to the company. The SHINE study demonstrated superiority in trough FEV1 for QVA 149 compared to indacaterol alone, glycopyrronium alone, tiotropium, and placebo in more than 2,000 patients with moderate … [Read more...] about QVA 149 Phase 3 studies meet primary endpoints
European rights to aclidinium bromide to Menarini, review period extended by the FDA
Almirall has licensed European rights to aclidinium bromide, both as a monotherapy and in combination with formoterol to Italian pharmaceutical company Menarini. The agreement covers most of the EU except for the UK, the Netherlands and the Nordic countries, plus several additional countries, including Russia and Turkey. Almirall CEO Eduardo Sanchiz explained, … [Read more...] about European rights to aclidinium bromide to Menarini, review period extended by the FDA